CAMPATH Pages on BioPortfolio:

Biotechnology News CAMPATH Search
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/CAMPATH-news.htm...

Campath Improves Survival of Refractory CLL Patients
15 May 2002 ... Campath demonstrated encouraging data in terms of overall objective ... Campath is indicated for use for the treatment of B-CLL in patients ...
http://www.bioportfolio.com/news/btech_051502_2.htm...

Biotechnology News LEUKINE Search
Genzyme's Campath Meets Primary Endpoint In Phase 3 Combination Therapy Trial ... oday that its randomized Phase 3 clinical trial investigating Campath(R) ...
http://www.bioportfolio.co.uk/LEUKINE-news.htm...

BioPortfolio - Campath
Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ...
http://www.bioportfolio.com/indepth/Campath.html...

BioPortfolio.com - BioWeb Thrombocytopenia Search
Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BioPortfolio - Bayer HealthCare Pharmaceuticals Inc. - Bayer ...
Read Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual · Meeting of the American Society of Hematology on ...
http://www.bioportfolio.com/news/Bayer_Announces_Upcoming_Pr...

BioPortfolio.com - BioWeb Pancytopenia Search
Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week should not be administered because these doses are associated ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BTG plc: Final Phase II Results of CampathR Multiple Sclerosis ...
23 Oct 2008 ... Results show a significant and sustained reduction in disability and risk of relapse for MS patients on Campath® versus those on Rebif® ...
http://www.bioportfolio.com/biotech_news/BTG_11.htm...

Biotechnology News Anemia Refractory Search
Genzymes Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia rovement in Progression Free Survival Seen in ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BioPortfolio - CD53 antigen Antibody Search
CD5, CD50 (ICAM-3), CD52 (Campath-1), CD53, CD54 (ICAM-1), CD55 (DAF) ... T cell surface glycoprotein, T lymphocyte differentiation antigen T8/Leu2, . ...
http://www.bioportfolio.com/antibody/CD53%20antigen.html...

Results from other life science and pharmaceutical sites:

Alemtuzumab - Wikipedia, the free encyclopedia
The origins of alemtuzumab date back to Campath-1 which was derived from the ... This became known as Campath-1H and serves as the basis for alemtuzumab. ...
http://en.wikipedia.org/wiki/Alemtuzumab...

Mooren's ulcer resolved with campath-1H
Campath-1H is a humanised lymphocytotoxic monoclonal antibody (mAb) that targets the CD52 antigen on T lymphocytes. Successful mAb therapy using campath-1H ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771776/...

Alemtuzumab (marketed as Campath) Information
9 Sep 2009 ... This is a summary of the most important information about Campath. For more information, talk to your healthcare professional. ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Population pharmacokinetics–pharmacodynamics of alemtuzumab ...
Alemtuzumab (Campath®) is a 150-kDa humanized IgG1 monoclonal antibody (MAb) ...... Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000651/...

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol ...
CAMPATH-1 antibodies recognize a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=11...

The effects of Campath 1H upon graft-versus-host disease ...
We performed a trial using Campath 1 H pre- and post-HSCT in an attempt to decrease the incidence of GVHD without increasing the risk of infection or ...
http://www.ncbi.nlm.nih.gov/pubmed/17448918...

CAMPATH: from concept to clinic
CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=15...

Synovial tissue response to treatment with Campath-1H.
Therapeutic trials in rheumatoid arthritis with the monoclonal antibody Campath- 1H have demonstrated recurrent clinical synovitis in some patients, ...
http://www.ncbi.nlm.nih.gov/pubmed/7531440...

Information for Healthcare Professionals - Alemtuzumab (marketed ...
9 Sep 2009 ... Campath is not approved for the treatment of MS. Campath is approved for treating B-cell chronic lymphocytic leukemia (CLL) in patients who ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Pharmacokinetics of CAMPATH-1H: assay development and validation.
CAMPATH-1H is a humanised monoclonal antibody against the CD52 antigen which is being developed for treatment of chronic lymphocytic leukaemia (CLL), ...
http://www.ncbi.nlm.nih.gov/pubmed/11792397...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.